Showing results (301-310 of 25,842) with videos related to
Sort By:
Pageof 2,585
Anticancer Research|July 1, 1997
Tumor marker concentrations in normal and malignant tissues of colorectal cancer patients and their prognostic relevanceG Gebauer, W Müller-RuchholtzAnticancer Research|July 1, 1997
Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancerK N Gaarenstroom, J M Bonfrer, C M Korse, et al.Anticancer Research|July 1, 1997
Screening for prostatic carcinoma with prostate specific antigenR Waidelich, H M Jansen, P Stieber, et al.Anticancer Research|July 1, 1997
The use of prostate-specific antigen (PSA) for the monitoring of radiation therapy in prostate cancerU Schäfer, O Micke, G Hampel, et al.Anticancer Research|July 1, 1997
Metastatic workup of patients with prostate cancer employing skeletal alkaline phosphataseJ M Wolff, T H Ittel, W Boeckmann, et al.Anticancer Research|July 1, 1997
Circadian variations of interleukin-2 receptors, serum thymidine kinase and beta-2-microglobulin in patients with non-Hodgkin's lymphoma and normal controlsO Micke, U Schäfer, B Wörmann, et al.Anticancer Research|July 1, 1997
Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myelomaS Poley, P Stieber, V Nüssler, et al.Anticancer Research|July 1, 1997
Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myelomaS Poley, P Stieber, V Nüssler, et al.Anticancer Research|July 1, 1997
Development of the Abbott AxSYM Free PSA assay: performance characteristics and preliminary clinical evaluationB Dowell, L Jacobson, J Friese, et al.Anticancer Research|July 1, 1997
UGP--a tumor marker of gynecologic and breast malignancies? Specificity and sensitivity in pretherapeutic patients and the influence of hormonal substitution on the expression of UGPU Schwarz-Roeger, B Petzoldt, R Waldschmidt, et al.Pageof 2,585